Expression of MMPs and TIMPs in liver fibrosis – a systematic review with special emphasis on anti-fibrotic strategies  Stefanie Hemmann, Jürgen Graf,

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Volume 53, Issue 1, Pages (July 2010)
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 46, Issue 3, Pages (March 2007)
The impact of hepatitis E in the liver transplant setting
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation  Martin Roderfeld, Timo Rath, Richard Schulz, Werner Seeger,
Volume 61, Issue 6, Pages (December 2014)
The impact of hepatitis E in the liver transplant setting
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Intrinsic Cellular Defenses against Human Immunodeficiency Viruses
NS5A inhibitors in the treatment of hepatitis C
Immigration and viral hepatitis
Ping Wang, Katelyn A. Doxtader, Yunsun Nam  Molecular Cell 
Volume 66, Issue 1, Pages 1-4 (January 2017)
The evidence supports a viral aetiology for primary biliary cirrhosis
Living donor liver transplantation: is the hype over?
David G. Bowen, Christopher M. Walker  Journal of Hepatology 
Hepatitis C core protein – The “core” of immune deception?
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Control of iron metabolism – Lessons from neonatal hemochromatosis
Inhibition of mammalian target of rapamycin: Two goals with one shot?
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Why men are at higher risk for hepatocellular carcinoma?
Volume 45, Issue 4, Pages (October 2006)
Volume 62, Issue 3, Pages (March 2015)
Advancing hepatitis B virus entry inhibitors
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
Therapeutic editing of hepatocyte genome in vivo
EASL Clinical Practice Guidelines: Wilson’s disease
Met as a therapeutic target in HCC: Facts and hopes
Economics of chronic hepatitis B and hepatitis C
Volume 10, Issue 3, Pages (March 2003)
Volume 57, Issue 5, Pages (November 2012)
The Editors' Choice Journal of Allergy and Clinical Immunology
Volume 50, Issue 4, Pages (April 2009)
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Paul C. Adams, James C. Barton  Journal of Hepatology 
miR-122 – A key factor and therapeutic target in liver disease
Chetana Lim, Chady Salloum, Daniel Azoulay
Immigration and viral hepatitis
Kornelius Schulze, Jean-Charles Nault, Augusto Villanueva 
Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability  Markus Cornberg,
Volume 63, Issue 1, Pages (July 2015)
Volume 51, Issue 2, Pages (August 2009)
The use of hemospray in portal hypertensive bleeding; a case series
Volume 66, Issue 4, Pages (April 2017)
Tatiana Kisseleva, David A. Brenner  Journal of Hepatology 
Volume 10, Issue 3, Pages (March 2003)
Liver transplantation in children
Ana Lleo, M. Eric Gershwin, Alberto Mantovani, Pietro Invernizzi 
Pathogenesis of cholestatic hepatitis C
Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing  Roongruedee Chaiteerakij,
Chimeric mouse model of hepatitis B virus infection
Corrigendum to “Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury” [J Hepatol 49 (2008) 88–98]  Angela Douglass,
Genetics of hepatocellular carcinoma: The next generation
Platelets arrive at the scene of fibrosis……studies
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Fondaparinux (Arixtra∗) hepatotoxicity in a 6 year-old child
The dawn of a new EASL – A new chapter in the history of the European Association for the Study of the liver  Tom H. Karlsen, Phil N. Newsome  Journal.
Presentation transcript:

Expression of MMPs and TIMPs in liver fibrosis – a systematic review with special emphasis on anti-fibrotic strategies  Stefanie Hemmann, Jürgen Graf, Martin Roderfeld, Elke Roeb  Journal of Hepatology  Volume 46, Issue 5, Pages 955-975 (May 2007) DOI: 10.1016/j.jhep.2007.02.003 Copyright © 2007 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Domain organization of different mammalian MMPs. GPI (glycosylphosphatidylinositol) membrane anchor. Journal of Hepatology 2007 46, 955-975DOI: (10.1016/j.jhep.2007.02.003) Copyright © 2007 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Mechanism of MMP inhibition by TIMP-1. (A) Structure of MMP-3 (yellow) showing the binding cleft in which the catalytic zinc ion (orange circle) is bound to three His in the active site. One coordination site of the zinc ion is occupied by a water molecule (not shown). Thus, permitting substrate binding. (B) TIMP-1 (blue) bound to active MMP-3 demonstrating the perfect structural fit of the two proteins. (C) Zoom into the active centre of MMP-3. Substrate binding of MMP-3 is inhibited by TIMP-1. N-terminal Cys1 amino group occupies the 4th coordination site of the zinc ion in the active centre. Graphics were generated based on PDB Database Entry No. 1UEA using PyMOL Software (www.pymol.org) [187]. Journal of Hepatology 2007 46, 955-975DOI: (10.1016/j.jhep.2007.02.003) Copyright © 2007 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Possible expression profiles of MMPs and TIMPs incorporating the current knowledge of the pathophysiology of chronic toxic liver injury. Differences in y-axis values are arbitrarily set for better understanding. Journal of Hepatology 2007 46, 955-975DOI: (10.1016/j.jhep.2007.02.003) Copyright © 2007 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Results of the systematic literature retrieval process via PubMed (refer to the text for the detailed search strategy). The number and reasons for study exclusion are given. Journal of Hepatology 2007 46, 955-975DOI: (10.1016/j.jhep.2007.02.003) Copyright © 2007 European Association for the Study of the Liver Terms and Conditions